HEALTH OF WOMAN. 2016.1(107):112–121 
 

Laboratory diagnosis of the individual components of the metabolic syndrome 
 

Kobyliak N. N., Kyriienko D. V.

A.A. Bogomolets National Medical University, Kiev

Kyiv city clinical endocrinology center 
 

The article highlights the issue of pathogenesis and modern methods of diagnosis of the metabolic syndrome and prediabetes. 
 

Key words: metabolic syndrome, prediabet, glycated hemoglobin, HOMA index, leptin, adiponectin. 
 

REFERENCES

1. Reaven GM. 1988. Role of insulin resistance in human disease. Diabetes. 37:1595–1607. http://dx.doi.org/10.2337/diab.37.12.1595; http://dx.doi.org/10.2337/diabetes.37.12.1595; PMid:3056758

2. Kaplan NM 1989. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch.Intern. Med. 149:1514–1520. http://dx.doi.org/10.1001/archinte.1989.00390070054005; http://dx.doi.org/10.1001/archinte.149.7.1514; PMid:2662932

3. Henefeld M, Leonhardt W. 1980. Das metabolische Syndrome. Deutsch. Ges. Wes. 36:545–551.

4. DeFronzo RA 2009. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture. Diabetologia 53;7:1270–1287. http://dx.doi.org/10.1007/s00125-010-1684-1; PMid:20361178 PMCid:PMC2877338

5. Calle EE, Thun MJ, Petrelli JM et al. 1999. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med. 341:1097–1105. http://dx.doi.org/10.1056/NEJM199910073411501; PMid:10511607

6. Must A, Spadano J, Coakley EH. 1999. The disease burden associated with overweight and obesity. JAMA. 282:1523–1529. http://dx.doi.org/10.1001/jama.282.16.1523; PMid:10546691

7. Ferrannini E, Natali A, Bell P et al. 1997. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 100:1166–1173. http://dx.doi.org/10.1172/JCI119628; PMid:9303923 PMCid:PMC508292

8. Brochu M, Tchernof A, Dionne IJ et al. 2001. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 86:1020–1025. http://dx.doi.org/10.1210/jc.86.3.1020; http://dx.doi.org/10.1210/jcem.86.3.7365; PMid:11238480

9. Karelis AD, Faraj M, Bastard JP et al. 2005. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 90:4145–4150. http://dx.doi.org/10.1210/jc.2005-0482; PMid:15855252

10. Karelis AD, Brochu M, Rabasa-Lhoret R. 2004. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 30:569–572. http://dx.doi.org/10.1016/S1262-3636(07)70156-8

11. Meigs JB, Wilson PW, Fox CS. 2006. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 91:2906–2912. http://dx.doi.org/10.1210/jc.2006-0594; PMid:16735483

12. Narthan DM, Davidson MB, De Fronzo RA et al. 2007. Impaired fasting glucose and impaired glucose tolerance: implication for care. Diabetes Care. 30:753–759. http://dx.doi.org/10.2337/dc07-9920; PMid:17327355

13. Stern SE, Williams K, Ferranini E et al. 2005. Identification of individuals with insulin resistance using routine measurements. Diabetes. 54:333–339. http://dx.doi.org/10.2337/diabetes.54.2.333; PMid:15677489

14. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009. 32;7:1327–1334. http://dx.doi.org/10.2337/dc09-9033; PMid:19502545 PMCid:PMC2699715

15. American Diabetes Associations. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010. S. suppl. 1:62–69.

16. Stroev YI, Choi MW, Churilov LP, Shishkin AN 2007. Classical and modern concepts of the metabolic syndrome. Part 2. Pathogenesis. Vestn. St. Petersburg Univ. Ser. 11, Vol. 4:3-15

17. Bjorntorp P. 1990. «Portal» adipose tissue as the generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493–496. http://dx.doi.org/10.1161/01.ATV.10.4.493; PMid:2196039

18. Fried SK, Russsell CD, Grauso NL, Brolin RE. 1991. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues from obese women and men. J Clin Invest. 92:2191–2198. http://dx.doi.org/10.1172/JCI116821; PMid:8227334 PMCid:PMC288398

19. Lundgren M, Buren J, Ruge T et al. 2004. Glucocorticoids down-regulate glucose uptake capacity and insulin-signalling proteins in omental but not subcutaneous adipocytes. J Clin Endocrinol Metab. 89:2989–2997. http://dx.doi.org/10.1210/jc.2003-031157; PMid:15181089

20. Malishev VA 2007. Dysfunction of adipose tissue as a crucial factor for development of diabetes mellitus type 2. Health Of Ukraine 10/1.

21. Randle PJ, Garland PB, Hales CN, Newsholme EA. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 13;1:785–789. http://dx.doi.org/10.1016/S0140-6736(63)91500-9

22. Thiebaud D, DeFronzo RA, Jacot E et al. 1982. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 31;11:1128–1136. http://dx.doi.org/10.1016/0026-0495(82)90163-9

23. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. 1983. Effect of fatty acids on glucose production and utilization in man. Journal of Clinical Investigation 72;5:1737–1747. http://dx.doi.org/10.1172/JCI111133; PMid:6138367 PMCid:PMC370462

24. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. 1993. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. Journal of Clinical Investigation 92;1:91–98. http://dx.doi.org/10.1172/JCI116603; PMid:8326021 PMCid:PMC293539

25. Dresner A, Laurent D, Marcucci M et al. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation. 103;2:253–259. http://dx.doi.org/10.1172/JCI5001; PMid:9916137 PMCid:PMC407880

26. Shulman GI. 2000. Cellular mechanisms of insulin resistance. Journal of Clinical Investigation 106;2:171–176. http://dx.doi.org/10.1172/JCI10583; PMid:10903330 PMCid:PMC314317

27. Holland WL, Brozinick JT, Wang LP et al. 2008. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5:167–179. http://dx.doi.org/10.1016/j.cmet.2007.01.002; PMid:17339025

28. Cai D, Yuan M, Frantz DF. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 11:183–190. http://dx.doi.org/10.1038/nm1166; PMid:15685173 PMCid:PMC1440292

29. Groop LC, Widйn E, Ferrannini E. 1993. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 36;12:1326–1331. http://dx.doi.org/10.1007/BF00400814; PMid:8307264

30. Mayorov A Y, Urbanova K A, Galstyan G R 2009. Methods for quantifying insulin resistance. Obesity and metabolism 2:19-23.

31. Alisheva, E K, Krasil'nikova E I, Shlyakhto E V 2002. Methods for early diagnosis of insulin resistance. Arterial hypertension 8;1:29-34.

32. DeFronzo RA, Tobin JD, Andres R. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 237;3:214–223.

33. Matthews DR, Hosker JP, Rudenski AS et al. 1985. Homeostasis model assessment: insulin resistance and b?cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28;7:412–419. http://dx.doi.org/10.1007/BF00280883

34. Wallace TM, Levy JC, Matthews DR. 2004. Use and abuse of HOMA modeling. Diabetes Care 27;6:1487–1495. http://dx.doi.org/10.2337/diacare.27.6.1487

35. Bonora E, Targher G, Alberichie M et al. 2000. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 23:57–63. http://dx.doi.org/10.2337/diacare.23.1.57; PMid:10857969

36. Garcia-Estevez DA, Araujo-Vilar D, Fiestras-Janeiro G. 2003. Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices. Horm Metab Res. 35:13–17. http://dx.doi.org/10.1055/s-2003-38385; PMid:12669265

37. Dedov II, Balabolkin MI, Mamaeva GG at al. 2005. Insulinovaya rezistentnost i rol gormonov zhirovoy tkani v razvitii saharnogo diabeta. Posobie dlya vrachey. Moskva:88.

38. Friedman JM. 2009. Leptin at 14 y of age: an ongoing story. Am. J. Clin. Nutr. 89(Suppl.):973–979. http://dx.doi.org/10.3945/ajcn.2008.26788B; PMid:19190071 PMCid:PMC2667654

39. Tartaglia LA, Dembski M, Weng X et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:1263–1271. http://dx.doi.org/10.1016/0092-8674(95)90151-5

40. Wang MY, Zhou Y, Newgard CB, Unger RH. 1998. A novel leptin receptor isoform in rat. FEBS Lett. 392:87–90. http://dx.doi.org/10.1016/0014-5793(96)00790-9

41. Lee GH, Proenca R, Montez JM et al. 1996. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 379:632–635. http://dx.doi.org/10.1038/379632a0; PMid:8628397

42. Minokoshi Y, Kahn BB. 2003. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem. Soc. Trans. 31:196–201. http://dx.doi.org/10.1042/bst0310196; PMid:12546684

43. Steinberg GR, Rush JWE, Dyck DJ. 2003. AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am. J. Physiol. Endocrinol. Metab. 284:648–654. http://dx.doi.org/10.1152/ajpendo.00318.2002; PMid:12441311

44. Mohammed J, Zobair Y. 2008. Adipokines and pathogenesis of non-alcoholic fatty liver disease. AnCha Baranova:192.

45. Lord GM, Matarese G, Howard JK et al. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 394;6696:897–901. http://dx.doi.org/10.1038/29795; PMid:9732873

46. Zhao T, Hou M, Xia M et al. 2005. Globular adiponectin decreases leptin-induced tumor necrosis factor-a expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol. 238;1:19–30. http://dx.doi.org/10.1016/j.cellimm.2005.12.002; PMid:16438946

47. Shen J, Sakaida I, Uchida K [et al.]. 2005. Leptin enhances TNF-a production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci. 77:1502–1515. http://dx.doi.org/10.1016/j.lfs.2005.04.004; PMid:15979653

48. Faggioni R, Jones-Carson J, Reed DA et al. 2000. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor-a and ІЛ-18. Proc. Natl Acad. Sci. USA. 97;5:2367–2372. http://dx.doi.org/10.1073/pnas.040561297; PMid:10681432 PMCid:PMC15807

49. Matarese G, Di Giacomo A, Sanna V et al. 2001. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J. Immunol. 166;10:5909–5916. http://dx.doi.org/10.4049/jimmunol.166.10.5909

50. Gorden P, Gavrilova O. 2003. The clinical uses of leptin. Curr Opin Pharmacol. 3:655–659. http://dx.doi.org/10.1016/j.coph.2003.06.006; PMid:14644019

51. Kobiljak NM, Kondro MM, Virchenko S, Falaleeva TM 2013. Pathophysiological role of leptin in development of obesity and related diseases. Experimental and clinical physiology and biochemistry 3(63):55-63.

52. Pajvani UB, Du X, Combs TP et al. 2003. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 278;11:9073 – 9085. http://dx.doi.org/10.1074/jbc.M207198200; PMid:12496257

53. Kobiljak NM, Mykhalchyshyn GP, Saukenuk OA, Falaleeva TM. 2013. Pathophysiological role of adiponectin in the development of obesity and related diseases. The world of Medicine and Biology 3(40);part 2:81-87.

54. Mykhalchyshyn GP, Bodnar PM, Kobiljak NM. 2013. Gpodisplayname in patients with type 2 diabetes mellitus with nonalcoholic fatty liver disease. Endocrinology 18;2:18-25.

55. Pajvani UB, Hawkins M, Combs TP et al. 2004. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279;13:12152–12162. http://dx.doi.org/10.1074/jbc.M311113200; PMid:14699128

56. Bobbert T, Rochlitz H, Wegewitz U et al. 2005. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 54;5:2712–2719. http://dx.doi.org/10.2337/diabetes.54.9.2712

57. Yamauchi T, Kamon J, Ito Y et al. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 423;6941:762–769. http://dx.doi.org/10.1038/nature01705; PMid:12802337

58. Kadowaki T, Yamauchi N, Kubota N et al. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116;7:1784–1792. http://dx.doi.org/10.1172/JCI29126; PMid:16823476 PMCid:PMC1483172

59. Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 6;10:772–783. http://dx.doi.org/10.1038/nri1937; PMid:16998510

60. Hara K, Boutin P, Mori Y et al. 2002. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 51:536–540. http://dx.doi.org/10.2337/diabetes.51.2.536; PMid:11812766

61. Vasseur F, Helbecque N, Dina C et al. 2002. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocytesecreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 11:2607–2614. http://dx.doi.org/10.1093/hmg/11.21.2607; PMid:12354786

62. Gu HF, Abulaiti A, Ostenson CG et al. 2004. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes. 53 (Suppl. 1):31–35. http://dx.doi.org/10.2337/diabetes.53.2007.S31

63. Whitehead JP, Richards AA, Hickman IJ. 2006. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 8;3:264–280. http://dx.doi.org/10.1111/j.1463-1326.2005.00510.x; PMid:16634986

64. Kubota N, Terauchi Y, Yamauchi T et al. 2002. Disruption adiponectin causes insulin resistance neo-intimal formation. J Biol Chem. 277:25863–25866. http://dx.doi.org/10.1074/jbc.C200251200; PMid:12032136

65. Maeda N, Shimomura I, Kishida K [et al.]. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 8:731–737. http://dx.doi.org/10.1038/nm724; PMid:12068289

66. Combs TP, Pajvani UB, Berg AH et al. 2004. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 145:367–383. http://dx.doi.org/10.1210/en.2003-1068; PMid:14576179

67. Yamauchi T, Kamon J, Minokoshi Y et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 8;11:1288–1295. http://dx.doi.org/10.1038/nm788; PMid:12368907

68. Wolf AM, Wolf D, Rumpold H et al. 2004. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323:630–635. http://dx.doi.org/10.1016/j.bbrc.2004.08.145; PMid:15369797

69. Kobayashi HN, Ouchi S, Kihara K et al. 2004. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 94;4:27–31. http://dx.doi.org/10.1161/01.RES.0000119921.86460.37; PMid:14752031 PMCid:PMC4374479

70. Fukuhara A, Matsuda M, Nishizawa M et al. 2007. Retraction. Science 318;5850:565.

71. Fukuhara A, Matsuda M, Nishizawa M et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307;5708:426–430. http://dx.doi.org/10.1126/science.1097243; PMid:15604363

72. Samal B, Sun Y, Stearns G et al. 2007. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14:1431–1437. http://dx.doi.org/10.1128/MCB.14.2.1431

73. Moschen AR, Kaser A, Enrich B et al. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178:1748–1758. http://dx.doi.org/10.4049/jimmunol.178.3.1748; PMid:17237424

74. Berndt J, Kloting N, Kralisch S et al. 2005. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:911–2916. http://dx.doi.org/10.2337/diabetes.54.10.2911

75. Dogru T, Sonmez A, Tasci I et al. 2005. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res. Clin. Pract. 76:24–29. http://dx.doi.org/10.1016/j.diabres.2006.07.031; PMid:16956691

76. Tilg H, Diehl AM. 2000. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med. 343:1467–1476. http://dx.doi.org/10.1056/NEJM200011163432007; PMid:11078773

77. Mykhalchyshyn G.P., Bodnar P.M., Kobiljak N.M.. 2014. The level of tumor necrosis factor alpha and its correlations in patients with type 2 diabetes mellitus with nonalcoholic fatty liver disease. Clinical endocrinology and endocrine surgery 1(46):33-40.

78. Tartaglia LA, Goeddel DV. 1992. Two TNF receptors. Immunol. Today 13:151–153. http://dx.doi.org/10.1016/0167-5699(92)90116-O

79. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87–91.

80. Uysal KT, Wiesbrock SM, Marino MW et al. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:610–614. http://dx.doi.org/10.1038/39335; PMid:9335502

81. Hirosumi J, Tuncman G, Chang L et al. 2002. A central role for JNK in obesity and insulin resistance. Nature. 21;420:333–336. http://dx.doi.org/10.1038/nature01137; PMid:12447443

82. Yuan M, Konstantopoulos N, Lee J et al. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-b. Science. 293:1673–1677. http://dx.doi.org/10.1126/science.1061620; PMid:11533494

83. Shoelson SE, Lee J, Yuan M. 2003. Inflammation and the IKK-b /I-kB/NF-kB axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 27:49–52. http://dx.doi.org/10.1038/sj.ijo.0802501; PMid:14704745

84. Gao Z, Hwang D, Bataille F et al. 2002. Serine phosphorylation of insulin receptor substrate 1 by inhibitor кB kinase complex. J. Biol. Chem. 277:48115–48121. http://dx.doi.org/10.1074/jbc.M209459200; PMid:12351658

85. Cai D, Yuan M, Frantz DF et al. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-кB. Nat. Med. 11:183–190. http://dx.doi.org/10.1038/nm1166; PMid:15685173 PMCid:PMC1440292

86. Hundal RS, Petersen KF, Mayerson AB et al. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109:1321–1326. http://dx.doi.org/10.1172/JCI0214955; PMid:12021247 PMCid:PMC150979

87. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720–3732. http://dx.doi.org/10.1182/blood-2010-07-273417; PMid:21304099 PMCid:PMC3083294

88. Moschen AR, Molnar C, Enrich B et al. 2011. Adipose and liver expression of IL-1 family members in morbid obesity and effects of weight loss. Mol Med. 17;7–8:840–845.

89. Mykhalchyshyn G.P., Bodnar P.M., Kobiljak N.M. 2013. The level of IL-1b and its correlations in patients with type 2 diabetes mellitus with nonalcoholic fatty liver disease. Endocrinology 4:21-28.

90. Nov O, Kohl A, Lewis EC et al. 2010. Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. Endocrinology 151:4247–4256. http://dx.doi.org/10.1210/en.2010-0340; PMid:20660063

91. Somm E, Cettour-Rose P, Asensio C et al. 2006. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia. 49:387–393. http://dx.doi.org/10.1007/s00125-005-0046-x; PMid:16385385

92. Owyang AM, Maedler K, Gross L et al. 2010. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and (beta)-cell function in the diet-induced obesity mouse model. Endocrinology 151:2515–2527. http://dx.doi.org/10.1210/en.2009-1124; PMid:20332197

93. Larsen CM, Faulenbach M, Vaag A et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 356:1517–1526. http://dx.doi.org/10.1056/NEJMoa065213; PMid:17429083

94. Kim KH, Lee K, Moon YS, Sul HS. 2001. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 276:11252–11256. http://dx.doi.org/10.1074/jbc.C100028200; PMid:11278254

95. Steppan CM, Bailey ST, Bhat S et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307–312. http://dx.doi.org/10.1038/35053000; PMid:11201732

96. Banerjee RR, Lazar MA. 2003. Resistin: molecular history and prognosis. J Mol Med. 81:218–226. PMid:12700889

97. Rangwala SM, Rich AS, Rhoades B et al. 2004. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes. 53:1937–1941. http://dx.doi.org/10.2337/diabetes.53.8.1937; PMid:15189975

98. Rajala MW, Obici S, Scherer PE, Rossetti L. 2005. Adipose-derived resistin and gut-derived resistin-like molecule- selectively impair insulin action on glucose production. J. Clin. Invest. 111:225–230. http://dx.doi.org/10.1172/JCI16521; PMid:12531878 PMCid:PMC151868

99. Satoh H, Nguyen MT, Miles PD et al. 2004. Adenovirus-mediated chronic ‘hyper-resistinemia’ leads to in vivo insulin resistance in normal rats. J. Clin. Invest. 114:224–231. http://dx.doi.org/10.1172/JCI20785; PMid:15254589 PMCid:PMC449745

100. Qi Y, Nie Z, Lee YS et al. 2006. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55:3083–3090. http://dx.doi.org/10.2337/db05-0615; PMid:17065346

101. Emanuelli B, Peraldi P, Filloux J et al. 2001. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor in the adipose tissue of obese mice. J. Biol. Chem. 276:47944–47949. PMid:11604392

102. Nagaev J, Smith U. 2001. Insulin resistence and type 2 diabetes are not related to resistin expression in human fat cells or skelet muscle. Biochem Biophys Re Commun. 285:561–564. http://dx.doi.org/10.1006/bbrc.2001.5173; PMid:11444881

103. Kielstein JT, Becker B, Graf S et al. 2003. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis. 42:62–66. http://dx.doi.org/10.1016/S0272-6386(03)00409-8

104. Vozarova B, Fernandez-Real JM, Knowler WC et al. 2003. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum. Genet. 112:409–413. PMid:12589429

105. Wang CZ, Wang Y, Di A et al. 2005. 5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channeldependent and-independent pathways. Biochem. Biophys. Res. Commun. 330:1073–1079. http://dx.doi.org/10.1016/j.bbrc.2005.03.093; PMid:15823553

106. Weigert C, Hennige AM, Brodbeck K et al. 2005. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am. J. Physiol. Endocrinol. Metab. 289:251–257. http://dx.doi.org/10.1152/ajpendo.00448.2004; PMid:15755769

107. Pickup JC. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823. http://dx.doi.org/10.2337/diacare.27.3.813; PMid:14988310

108. Vozarova B, Weyer C, Hanson K et al. 2001. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9:414–417. http://dx.doi.org/10.1038/oby.2001.54; PMid:11445664

109. Bastard JP, Maachi M, Van Nhieu JT et al. 2002. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 87:2084–2089. http://dx.doi.org/10.1210/jcem.87.5.8450; PMid:11994345

110. Carrey AL, Bruce CR, Sacchetti M et al. 2004. Interleukin-6 and tumor necrosis factor – alpha are not increased in petients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 47:1029–1037.

111. Rotter V, Nagaev I, Smith U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278:45777–45784. http://dx.doi.org/10.1074/jbc.M301977200; PMid:12952969

112. Fasshauer M, Kralisch S, Klier M et al. 2003. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301:1045–1050. http://dx.doi.org/10.1016/S0006-291X(03)00090-1

113. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. 2003. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789. http://dx.doi.org/10.2337/diabetes.52.11.2784; PMid:14578297

114. Rieusset J, Bouzakri K, Chevillotte E [et al.]. 2004. Suppressor of cytokine signalling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232–2241. http://dx.doi.org/10.2337/diabetes.53.9.2232; PMid:15331532

115. Wallenius V, Wallenius K, Ahren B et al. 2002. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8:75–79. http://dx.doi.org/10.1038/nm0102-75; PMid:11786910

116. Kim HJ, Higashimori T, Park SY et al. 2004. Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes. 53:1060–1067. http://dx.doi.org/10.2337/diabetes.53.4.1060; PMid:15047622

117. Mooney RA. 2007. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102:816–818. http://dx.doi.org/10.1152/japplphysiol.01208a.2006; PMid:17284655

118. Lee MD, Zentella A, Vine W et al. 1987. Effect of endotoxin-induced monokines on glukose metabolism in the muscle cell line L6. Proc. Natl. Alad. Sci. USA. 84:2590–2594. http://dx.doi.org/10.1073/pnas.84.9.2590

119. Schwartz V. 2010. Dual role of interleukin-6 in the development of insulin resistance. Pathological physiology and experimental therapy 1:40-47.